Dr. Shi earned his medical degree at the Third Military Medical University at Chongqing, China. He got his first job as a resident physician and completed his Internal Medicine training at Daping Hospital affiliated to the Third Military Medical University, where he also obtained his Masters degree in Internal Medicine (Haematology). The research project for his Masters degree was immunophenotyping of acute leukaemias.
In 1995, Dr. Shi was appointed as lecturer and attending physician in haematology, with his research interests mainly focused on acute myeloid leukaemias. He got his Doctor’s degree in Internal Medicine in 2003 at Shanghai Second Medical University (Now Shanghai Jiaotong University School of Medicine). The main project for his Doctor’s degree was the study of the synergism of all-trans retinoic acid and arsenic trioxide in the treatment of acute promyelocytic leukaemia. Another project for his Doctor’s degree was pharmacogenomics of anti-leukaemic drugs in acute myeloid leukaemia. After completing his Doctor’s degree, he worked as a research fellow at the same institute for a short period of time and then returned to Chongqing taking up his role as a lecturer and attending physician in haematology.
Dr. Shi moved to Queen’s University Belfast in late 2004, working as postdoctoral research fellow, with his research interests being focused on functionality of erythropoietin receptor on tumour cells. In early 2010, Dr. Shi joined Kingston University London as a lecturer, then senior lecturer in haematology, with his main research interests still being in functionality of erythropoietin receptor on tumour cells and molecular mechanisms of leukaemia therapeutics. He got his Postgraduate Certificate in Learning and Teaching in Higher Education at Kingston University in 2012.
In late 2015, Dr. Shi joined Middlesex University as a senior lecturer in biomedical science. He is now the programme leader for MSc Biomedical Science (Haematology and Transfusion Science). His current research interests include erythropoietin receptor signalling pathways in tumour cells, molecular mechanism of the synergism between all-trans retinoic acid and arsenic trioxide in the treatment of acute promyelocytic leukaemia, the role of epigenetics in leukaemogenesis and the possibility as drug target, and the role of bone marrow microenvironment in haematological malignancies.
English and Chinese
Haematology and transfusion science
Current research interests
Erythropoietin receptor signalling pathways in tumour cells
Molecular mechanisms of leukaemia therapeutics
Role of bone marrow microenvironment in haematological malignancies
Role of epigenetics in leukaemogenesis and the possibility as drug target
Orr KS, Shi Z, Brown WM, O'Hagan KA, Lappin TR, Maxwell P, Percy MJ. Potential prognostic marker ubiquitin carboxyl-terminal hydrolase-L1 does not predict patient survival in non-small cell lung carcinoma. J Exp Clin Cancer Res. 2011; 30:79.
Lopez TV, Lappin TR, Maxwell P, Shi Z, Lopez-Marure R, Aguilar C, Rocha-Zavaleta L. Autocrine/paracrine erythropoietin signalling promotes JAK/STAT-dependent proliferation of human cervical cancer cells. Int J Cancer. 2011; 129(11):2566-76.
El-Tanani MK, Yuen HF, Shi Z, Platt-Higgins A, Buckley NE, Mullan PB, Harkin DP, Johnston PG, Rudland PS. Osteopontin can act as an effector for a germline mutation of BRCA1 in malignant transformation of breast cancer-related cells. Cancer Sci. 2010;101(6):1354-1360
Shi Z, Hodges VM, Dunlop EA, Percy MJ, Maxwell AP, El-Tanani M, Lappin TR. Erythropoietin-induced activation of the JAK2/STAT5, PI3K/Akt, and Ras/ERK pathways promotes malignant cell behavior in a modified breast cancer cell line. Mol Cancer Res. 2010;8(4):615-626
Brown WM, Maxwell P, Graham AN, Yakkundi A, Dunlop EA, Shi Z, Johnston PG, Lappin TR. Erythropoietin receptor expression in non-small cell lung carcinoma: a question of antibody specificity. Stem Cells 2007;25(3):718-722
Zhang SJ, Shi JY, Zhu YM, Shi ZZ, Yan-Sheng, Gu BW, Bai XT, Shen ZX, Li JY. The investigation of mutation and single nucleotide polymorphism of receptor tyrosine kinases and downstream scaffold molecules in acute myeloid leukemia. Leuk Lymphoma 2006;47(12):2610-2616
Shi JY, Shi ZZ, Zhang SJ, Zhu YM, Gu BW, Li G, Bai XT, Gao XD, Hu J, Jin W, et al. Association between single nucleotide polymorphisms in deoxycytidine kinase and treatment response among acute myeloid leukaemia patients. Pharmacogenetics 2004;14(11):759-768
Shen ZX, Shi ZZ, Fang J, Gu BW, Li JM, Zhu YM, Shi JY, Zheng PZ, Yan H, Liu YF, et al. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A. 2004;101(15):5328-5335
Gu BW, Wang Q, Wang JM, Xue YQ, Fang J, Wong KF, Chen B, Shi ZZ, Shi JY, Bai XT, et al. Major form of NUP98/HOXC11 fusion in adult AML with t(11;12)(p15;q13) translocation exhibits aberrant trans-regulatory activity. Leukemia 2003;17(9):1858-1864
Chen XL, Shi ZZ, Pu XY, et al. [Clinical significance of TGF-beta1, TGF-Rl and TGF-R2 determination in patients with myelofibrosis. Acta Academiae Medicinae Militaris Tertiae] (Chinese) 2001;23(4):457-458
Shi ZZ, Zhang PB, Wang QY, et al. [Clinical significance of expression of TGF-b1 and its 2 receptors (TGF-R1 and TGF-R2) in serum and bone marrow of patients with acute leukaemia]. Acta Academiae Medicinae Militaris Tertiae (Chinese) 2000; 22(8): 804-806
Fellow of the Higher Education Academy (from 2012)
Membership of the American Society of Haematology (from 2011)
Membership of European Haematology Association (from 2011)
Membership of the British Society for Haematology (from 2008)